Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New York AMSTERDAM, the Netherlands–(BUSINESS WIRE)–Scenic…